Recombinant Mouse Hydroxycarboxylic acid receptor 2 (Hcar2)

Basic Research Questions

• What is mouse HCAR2 and what is its significance in research?

  Mouse Hydroxycarboxylic acid receptor 2 (HCAR2, also known as GPR109A, PUMA-G, or Niacr1) is a class A G protein-coupled receptor that plays key roles in regulating lipolysis and free fatty acid formation. HCAR2 is highly expressed in multiple cell types, including adipocytes, vascular endothelium, immune cells, retinal pigmented cells, colonic epithelial cells, keratinocytes, and microglia . The receptor mediates downstream signaling primarily by coupling to the Gi/o family of G proteins .

  HCAR2 has gained significant research attention due to its involvement in numerous pathophysiological processes, making it an attractive target for studying cardiovascular, neoplastic, autoimmune, neurodegenerative, inflammatory, and metabolic diseases . Mouse models are particularly valuable for studying HCAR2 function as they allow for genetic manipulation and disease modeling.

• What are the key structural features of mouse HCAR2?

  Mouse HCAR2 consists of 360 amino acids and shares significant structural homology with human HCAR2 . Recent cryo-EM structures have revealed critical structural features of HCAR2, including:

  • Three key residues (R111³·³⁶, S179⁴⁵·⁵², and Y284⁷·⁴³) that form the general pharmacophore features for HCAR2 agonists .

  • A unique extracellular architecture where ECL2 is closely clamped by ECL1 and ECL3, and compressed by the N-terminus from the top .

  • Three disulfide bonds (C100³·²⁵-C177⁴⁵·⁵⁰, C18ᴺ⁻ᵗᵉʳᵐ-C183⁵·³³, C19ᴺ⁻ᵗᵉʳᵐ-C266⁷·²⁵) that are crucial for receptor stability and function .

  The recombinant mouse HCAR2 protein typically includes a full-length sequence (1-360aa) and may be fused with tags (such as His) for purification and detection purposes .

• How does mouse HCAR2 signaling function at the molecular level?

  HCAR2 signaling involves several key molecular mechanisms:

  • Upon activation, HCAR2 undergoes conformational changes characterized by an outward shift of the cytoplasmic side of TM6, which is consistent with the active state of class A GPCRs .

  • This conformational change permits insertion of the C-terminus of Gi protein .

  • The receptor primarily couples to Gi/o proteins, inhibiting adenylyl cyclase and reducing cAMP levels .

  • Distinct domains within the C-terminal tail of HCAR2 play crucial roles in:

    • Receptor export to the cell surface

    • Constitutive activity

    • Desensitization

    • Phosphorylation

    • Internalization

  Notably, a sequence from residues 329 to 343 in the C-terminal tail plays a critical role in maintaining HCAR2 in an inactive conformation .

Intermediate Research Questions

• What experimental approaches are recommended for studying recombinant mouse HCAR2?

  Several effective experimental approaches for studying recombinant mouse HCAR2 include:

  • Expression systems: E. coli expression systems have been successfully used to produce recombinant full-length mouse HCAR2 with N-terminal His tags .

  • Functional assays:

    • cAMP accumulation assays to assess Gi-coupled signaling

    • CRE-driven luciferase activity assays for receptor functionality

    • ERK1/2 activation assays to monitor downstream signaling

    • Calcium mobilization using Fura-2AM for measuring intracellular calcium responses

  • Localization studies:

    • Confocal microscopy with membrane markers such as DiI

    • ELISA analyses to quantify cell surface expression versus total cellular expression

  • Reporter systems:

    • The HCAR2 mRFP (Gpr109a mRFP) reporter mouse line, where the HCAR2 locus directs the expression of monomeric red fluorescent protein, provides a valuable tool for visualizing receptor expression in vivo .

• How can researchers effectively generate and validate HCAR2 knockout mouse models?

  Generating and validating HCAR2 knockout models requires careful methodology:

  • Global knockout: HCAR2⁻/⁻ (Hcar2⁻/⁻) mice have been widely used to study the receptor's function. These knockout mice show no overt phenotype if unchallenged but display significant differences in disease models .

  • Conditional knockout: Cell-specific knockout models (such as HCAR2ᶠˡᵒˣᵖᶜˣᶜ³ʳ¹ ᶜʳᵉ) can be generated to study HCAR2 function in specific cell types, such as microglia .

  • Validation methods:

    • RT-PCR to confirm absence of HCAR2 mRNA expression

    • Western blotting to verify protein absence

    • Functional assays to demonstrate loss of HCAR2-mediated responses

    • Testing with HCAR2 agonists (like niacin or β-hydroxybutyrate) to confirm lack of response in knockout models

  • Experimental design considerations:

    • Include appropriate littermate controls

    • Consider that compensatory mechanisms may develop in global knockout models

    • For microglia-specific studies, depletion using CSF1R antagonists (e.g., PLX5622) can help validate HCAR2's role specifically in these cells

• What are the most effective agonists for studying mouse HCAR2 function?

  Several agonists have been characterized for studying mouse HCAR2 function, each with specific properties:

  Agonist	Description	Application	Flush Response
  Niacin	Endogenous ligand, high affinity	Generally used at 10-25μM in vitro	Associated with flushing side effect
  β-hydroxybutyrate (BHB)	Endogenous ketone body	Used at 3mg/mL in drinking water for in vivo studies	Limited flushing
  Acipimox	Synthetic drug	Similar binding mode to niacin	Associated with flushing
  MK-6892	Highly subtype-specific agonist	Shows extended binding pocket relative to other agonists	Limited flushing
  GSK256073	Synthetic agonist	High potency	Limited flushing
  Dimethyl fumarate (DMF)	Active metabolite: monomethyl fumarate (MMF)	Used for therapeutic studies in disease models	Limited flushing

  Recent structural studies have revealed that despite differences in flushing side effects, both "flushing" and "non-flushing" agonists exhibit similar binding modes, suggesting that the mechanisms behind these differential effects may involve factors beyond simple receptor binding .

Advanced Research Questions

• How does HCAR2 regulate microglial responses in neurodegenerative disease models?

  HCAR2 plays a significant role in regulating microglial responses in neurodegenerative diseases through several mechanisms:

  • Expression pattern: HCAR2 is robustly induced in microglia in response to amyloid pathology in Alzheimer's disease (AD) models. Transcriptomic data shows significantly increased HCAR2 expression in microglia associated with neuritic Aβ plaques .

  • Knockout effects: Genetic inactivation of HCAR2 in 5xFAD mice (AD model) impairs microglial response to amyloid pathology, resulting in:

    • Exacerbation of plaque burden

    • Increased neuronal pathology

    • Cognitive impairment

  • Activation benefits: Activation of HCAR2 with approved formulations of niacin (Niaspan) stimulates a protective microglial response leading to:

    • Decreased plaque burden

    • Reduced neuronal loss

    • Improved working memory

  • Signaling mechanisms: In microglia, HCAR2 activation can inhibit NF-κB phosphorylation and modulate inflammatory cytokine production. Some agonists (like MMF) operate through a calcium-dependent signaling pathway, while others may utilize AMPK/Sirt1-independent mechanisms .

  For experimental design, researchers should consider combining transcriptomic analysis of sorted microglia, immunohistochemistry, behavioral testing, and pharmacological interventions with HCAR2 agonists to comprehensively assess microglial responses.

• What are the methodological challenges in studying HCAR2-mediated signaling and how can they be addressed?

  Several methodological challenges exist in studying HCAR2-mediated signaling:

  • Ligand selectivity: HCAR2 shares significant homology with other hydroxycarboxylic acid receptors, making ligand selectivity challenging. Recent structural insights have identified key residues that determine ligand selectivity between HCAR2 and HCAR3 . Researchers should carefully validate receptor specificity using knockout controls and selective agonists.

  • Receptor desensitization: HCAR2 undergoes rapid desensitization and internalization following activation. Mutants with C-terminal deletions between Arg315 to Ser328 or alanine substitutions for Ser326, Thr327, and Ser328 show deficiencies in arrestin3 binding, receptor internalization, phosphorylation, and desensitization . Consider the timing of measurements in signaling assays to account for desensitization kinetics.

  • Cell-type specific effects: HCAR2 activation can produce different outcomes in different cell types. For example, MMF signaling through HCAR2 can involve calcium signaling in some cells while utilizing NF-κB inhibition in others . When designing experiments, use cell-type specific knockout models or isolated primary cells to account for these differences.

  • Constitutive activity: The C-terminal region (residues 329-343) plays a crucial role in maintaining HCAR2 in an inactive conformation. Deletion of this region results in constitutive activity . Careful consideration of baseline activity is important when interpreting experimental results.

• How can HCAR2 be effectively targeted in inflammatory and neurodegenerative disease models?

  Effectively targeting HCAR2 in disease models requires strategic approaches:

  • Pharmacological targeting:

    • For Alzheimer's disease: FDA-approved niacin formulations (Niaspan) stimulate a protective microglial response that reduces plaque burden and improves memory .

    • For Parkinson's disease: Nicotinic acid (NA) administration (3mg/mL in drinking water) activates HCAR2 to regulate microglial responses and alleviate neuroinflammation .

    • For multiple sclerosis: Dimethyl fumarate (DMF) mediates protective effects through HCAR2, reducing neurological deficit and immune cell infiltration .

  • Experimental design considerations:

    • Duration: Long-term studies (4+ weeks) are necessary to observe meaningful effects on disease progression .

    • Route of administration: Oral administration (drinking water or gavage) is commonly used for compounds like niacin (30mg/kg, twice daily) .

    • Assessment parameters should include:

      • Behavioral tests (open field, pole-climbing, rotor experiments)

      • Histopathological evaluation

      • Inflammatory marker analysis

      • Cell-specific responses

  • Translational potential:

    • Research suggests activation of HCAR2 has therapeutic potential across multiple neurodegenerative diseases .

    • The presence of already-approved HCAR2 agonists (niacin, DMF) facilitates potential clinical translation.

• What role does HCAR2 play in retinal inflammation and how can it be studied in mouse models?

  HCAR2 plays a significant role in regulating retinal inflammation and immunity:

  • Expression pattern: HCAR2 is expressed in retinal pigment epithelial (RPE) cells, microglia, and endothelial cells in the retina .

  • Functional significance:

    • HCAR2 knockout mice exhibit progressive anomalies in retinal morphology and function affecting the entire retina .

    • Gene expression and protein interactome analyses of knockout mice reveal differences consistent with increased immune reactivity and infiltration of bone-marrow derived immune cells .

  • Therapeutic potential:

    • Targeting HCAR2 with β-hydroxybutyrate limits immune cell activation, infiltration, and related inflammation in wild-type mouse retinas in models of endotoxin-induced inflammation .

  • Methodological approaches:

    • Functional assessment: Electroretinography (ERG) to evaluate retinal function longitudinally

    • Imaging: Fundoscopic imaging, spectral domain-optical coherence tomography (OCT), and fluorescein angiography

    • Histological analysis: Post-mortem histological analyses to evaluate retinal health

    • Molecular profiling: Gene microarray, RT-qPCR studies, ingenuity analyses, and proteome pathway mapping

    • Immune cell analysis: Leukostasis and flow cytometric assays to demonstrate the impact of HCAR2 on pro-inflammatory immune cell trafficking in retina

  These findings highlight HCAR2 as a major regulator of retinal immune responses under normal conditions and as a high-potential therapeutic target for modulating inflammatory responses in retinal diseases.